Galena Biopharma ($GALE) believes that its experienced oncology sales team will enable it to effectively market Zuplenz, the only oral soluble film for preventing vomiting following chemotherapy and radiotherapy, which it will soon offer thanks to a licensing agreement struck with MonoSol Rx, the developer of the product's delivery technology. "Adding Zuplenz to our commercial portfolio enhances our offering of supportive care products that are simple to take and provide reliable dosing to improve the quality of life for patients suffering from cancer or recovering from surgery and the associated side-effects," said Galena Biopharma CEO Mark Ahn in a statement. Zuplenz contains ondansetron, which inhibits the neurotransmitter serotonin, thereby reducing nausea and vomiting. Galena says the oral thin strip version of the drug, administered via the top of the tongue, works better than the tablet formulation because it eliminates the burden of swallowing pills during episodes of vomiting, resulting in improved patient compliance. Release